Early detection of MRD in peripheral blood after induction chemotherapy of newly diagnosed patients with AML and its correlation with curative effects.
10.7534/j.issn.1009-2137.2013.01.013
- Author:
Xu-Shu ZHONG
1
;
Fei LAN
;
Xu CUI
;
Neng-Gang JIANG
;
Huan-Ling ZHU
;
Yong-Qian JIA
Author Information
1. Department of Hematology, Sichuan University, Chengdu, Sichuan Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Early Diagnosis;
Female;
Flow Cytometry;
Humans;
Leukemia, Myeloid, Acute;
blood;
drug therapy;
mortality;
Male;
Middle Aged;
Neoplasm, Residual;
diagnosis;
drug therapy;
mortality;
Prognosis;
Survival Rate;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(1):57-61
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to detect the minimal residual disease (MRD) in peripheral blood of newly diagnosed patients with acute myeloid leukemia (AML) on day 8 of induction chemotherapy and analyze the correlation between day 8 MRD (D8RD) and therapeutic effectiveness. 29 adult patients (13 males and 16 females, aged 16 - 75 years, median 41 years) with AML diagnosed and treated in West China Hospital from September 2009 to June 2010 were analyzed and followed up in the study. The leukemia-associated aberrant immunophenotype (LAIP) of all the patients were detected by multiparameter flow cytometry (FCM) before therapy. The level of MRD in the peripheral blood at day 8 of induction chemotherapy was detected by FCM based on the LAIP. The overall survival curve was drawn by calculation using Kaplan-Meier method using, and the comparison between different groups was carried out by Log-rank test. The results indicated that after first course therapy, the levels of peripheral D8RD in 7 out of 29 AML cases were lower than 0.01% (negative group), and that in another 22 cases were higher than 0.01% (0.08% - 55%, positive group). The sex, age, WBC, LDH, percentage of bone marrow blasts at diagnosis in these groups were not statistically different. 6 cases achieved CR (86%) in D8RD negative group, and also 6 cases achieved CR (27%) in D8RD positive group, CR rate in D8RD negative group was higher than in D8RD positive group (86% vs 27%, P < 0.05). The median follow-up of 29 cases lasted for 15 months; the 1-year overall survival rate of D8RD negative and D8RD positive groups was 100% and 39.4%, respectively (P < 0.01). It is concluded that MRD level in peripheral blood at day 8 of induction chemotherapy is an early index to predict clinical efficacy of induction therapy in AML.
